Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours. These results were presented after market close at an AACR Special Conference in Cancer Research. “Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive… Read More
This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More
This is the latest episode of the free DDW narrated podcast, titled ‘Exciting start-ups and developments in drug discovery’, which covers two articles written for DDW Volume 24 – Issue 1, Winter 2022/2023. They are called: ‘What Lithuania offers life sciences start-ups’ and ‘… Read More
World Pancreatic Cancer Day takes place on 21 November to raise awareness about pancreatic cancer, support patients and their families, and advocate for increased research and early detection of this deadly disease. iOnctura’s Chief Medical Officer Michael Lahn discusses how we can fight the disease by breaking the defensive wall… Read More
Megan Thomas spoke with Dan Passeri, CEO of Cue Biopharma, about why the company’s pipeline of cytokine-based drugs are so promising for cancer treatment. MT: Why is this a promising area of oncology research? DP: Cytokines, such as interleukin 2 (IL-2), are potent immunostimulant molecules and well-characterised activators of T… Read More
Megan Thomas comments and speaks with experts to uncover the future of cancer research. Artificial intelligence (AI) It’s not whether AI should be used, it’s when and how. Until several hurdles are overcome, such as data quality, data privacy and security, as well as regulatory and ethical challenges, this is… Read More
This Breast Cancer Awareness Month, Diana Spencer takes a look at the current situation and the new therapies on the horizon. Breast cancer is the most common cancer globally, with around 2.3 million new cases every year, according to data from the World Health Organization (WHO). Read More
DDW’s Megan Thomas interviews Dr Oren Gilad, President and CEO of Aprea Therapeutics, about the company’s targeted therapeutics that overcome the traditional issues associated with chemotherapy such as toxicity and tumour resistance. MT: Can you provide an overview of Aprea Therapeutics’ approach to developing new cancer therapies… Read More
Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. This eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments. Download this exclusive eBook… Read More
Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action. Turning points and catalysts… Read More
This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for… Read More
The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study. The trial is being run by NH TherAguix, a biotechnology company developing… Read More
Twenty-three companies will benefit from a share of £12 ($15.8) million from the Innovate UK Cancer Therapeutics programme. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing unmet medical needs for treating childhood and young persons’… Read More
Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02. TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer,… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The chosen news highlights this week all feature advances in drug development in oncology… Read More
Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format. The chosen news highlights this… Read More
